Literature DB >> 25274782

Cytoplasmic sequestration of FUS/TLS associated with ALS alters histone marks through loss of nuclear protein arginine methyltransferase 1.

Michael Tibshirani1, Miranda L Tradewell1, Katie R Mattina1, Sandra Minotti1, Wencheng Yang2, Hongru Zhou3, Michael J Strong2, Lawrence J Hayward3, Heather D Durham4.   

Abstract

Mutations in the RNA-binding protein FUS/TLS (FUS) have been linked to the neurodegenerative disease amyotrophic lateral sclerosis (ALS). Although predominantly nuclear, this heterogenous nuclear ribonuclear protein (hnRNP) has multiple functions in RNA processing including intracellular trafficking. In ALS, mutant or wild-type (WT) FUS can form neuronal cytoplasmic inclusions. Asymmetric arginine methylation of FUS by the class 1 arginine methyltransferase, protein arginine methyltransferase 1 (PRMT1), regulates nucleocytoplasmic shuttling of FUS. In motor neurons of primary spinal cord cultures, redistribution of endogenous mouse and that of ectopically expressed WT or mutant human FUS to the cytoplasm led to nuclear depletion of PRMT1, abrogating methylation of its nuclear substrates. Specifically, hypomethylation of arginine 3 of histone 4 resulted in decreased acetylation of lysine 9/14 of histone 3 and transcriptional repression. Distribution of neuronal PRMT1 coincident with FUS also was detected in vivo in the spinal cord of FUS(R495X) transgenic mice. However, nuclear PRMT1 was not stable postmortem obviating meaningful evaluation of ALS autopsy cases. This study provides evidence for loss of PRMT1 function as a consequence of cytoplasmic accumulation of FUS in the pathogenesis of ALS, including changes in the histone code regulating gene transcription.
© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25274782      PMCID: PMC4291251          DOI: 10.1093/hmg/ddu494

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  49 in total

1.  Structural insights into protein arginine symmetric dimethylation by PRMT5.

Authors:  Litao Sun; Mingzhu Wang; Zongyang Lv; Na Yang; Yingfang Liu; Shilai Bao; Weimin Gong; Rui-Ming Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production.

Authors:  Kevin Bonham; Saskia Hemmers; Yeon-Hee Lim; Dawn M Hill; M G Finn; Kerri A Mowen
Journal:  FEBS J       Date:  2010-03-22       Impact factor: 5.542

Review 3.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

4.  Methylation of histone H4 at arginine 3 occurs in vivo and is mediated by the nuclear receptor coactivator PRMT1.

Authors:  B D Strahl; S D Briggs; C J Brame; J A Caldwell; S S Koh; H Ma; R G Cook; J Shabanowitz; D F Hunt; M R Stallcup; C D Allis
Journal:  Curr Biol       Date:  2001-06-26       Impact factor: 10.834

5.  Extraction, purification and analysis of histones.

Authors:  David Shechter; Holger L Dormann; C David Allis; Sandra B Hake
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

6.  ALS-associated mutation FUS-R521C causes DNA damage and RNA splicing defects.

Authors:  Haiyan Qiu; Sebum Lee; Yulei Shang; Wen-Yuan Wang; Kin Fai Au; Sherry Kamiya; Sami J Barmada; Steven Finkbeiner; Hansen Lui; Caitlin E Carlton; Amy A Tang; Michael C Oldham; Hejia Wang; James Shorter; Anthony J Filiano; Erik D Roberson; Warren G Tourtellotte; Bin Chen; Li-Huei Tsai; Eric J Huang
Journal:  J Clin Invest       Date:  2014-02-10       Impact factor: 14.808

7.  Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations.

Authors:  Miranda L Tradewell; Zhenbao Yu; Michael Tibshirani; Marie-Chloé Boulanger; Heather D Durham; Stéphane Richard
Journal:  Hum Mol Genet       Date:  2011-09-28       Impact factor: 6.150

8.  H4R3 methylation facilitates beta-globin transcription by regulating histone acetyltransferase binding and H3 acetylation.

Authors:  Xingguo Li; Xin Hu; Bhavita Patel; Zhuo Zhou; Shermi Liang; River Ybarra; Yi Qiu; Gary Felsenfeld; Jörg Bungert; Suming Huang
Journal:  Blood       Date:  2010-01-12       Impact factor: 22.113

Review 9.  Protein arginine methylation in mammals: who, what, and why.

Authors:  Mark T Bedford; Steven G Clarke
Journal:  Mol Cell       Date:  2009-01-16       Impact factor: 17.970

10.  Neurofilament light and polyadenylated mRNA levels are decreased in amyotrophic lateral sclerosis motor neurons.

Authors:  C Bergeron; K Beric-Maskarel; S Muntasser; L Weyer; M J Somerville; M E Percy
Journal:  J Neuropathol Exp Neurol       Date:  1994-05       Impact factor: 3.685

View more
  24 in total

Review 1.  Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease.

Authors:  Seth A Bennett; Royena Tanaz; Samantha N Cobos; Mariana P Torrente
Journal:  Transl Res       Date:  2018-10-12       Impact factor: 7.012

2.  Quantitative proteomics identifies proteins that resist translational repression and become dysregulated in ALS-FUS.

Authors:  Desiree M Baron; Tyler Matheny; Yen-Chen Lin; John D Leszyk; Kevin Kenna; Katherine V Gall; David P Santos; Maeve Tischbein; Salome Funes; Lawrence J Hayward; Evangelos Kiskinis; John E Landers; Roy Parker; Scott A Shaffer; Daryl A Bosco
Journal:  Hum Mol Genet       Date:  2019-07-01       Impact factor: 6.150

Review 3.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era.

Authors:  Ximena Paez-Colasante; Claudia Figueroa-Romero; Stacey A Sakowski; Stephen A Goutman; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

Review 4.  Linking RNA Dysfunction and Neurodegeneration in Amyotrophic Lateral Sclerosis.

Authors:  Sami J Barmada
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

5.  Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models.

Authors:  Seth A Bennett; Samantha N Cobos; Marcella Meykler; Michel Fallah; Navin Rana; Karen Chen; Mariana P Torrente
Journal:  J Vis Exp       Date:  2019-03-24       Impact factor: 1.355

Review 6.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

Review 7.  The impact of histone post-translational modifications in neurodegenerative diseases.

Authors:  Samantha N Cobos; Seth A Bennett; Mariana P Torrente
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-10-20       Impact factor: 5.187

8.  Neurodegenerative Disease Proteinopathies Are Connected to Distinct Histone Post-translational Modification Landscapes.

Authors:  Karen Chen; Seth A Bennett; Navin Rana; Huda Yousuf; Mohamed Said; Sadiqa Taaseen; Natalie Mendo; Steven M Meltser; Mariana P Torrente
Journal:  ACS Chem Neurosci       Date:  2018-01-08       Impact factor: 4.418

Review 9.  Histone Methylation Regulation in Neurodegenerative Disorders.

Authors:  Balapal S Basavarajappa; Shivakumar Subbanna
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

10.  Toxic gain of function from mutant FUS protein is crucial to trigger cell autonomous motor neuron loss.

Authors:  Jelena Scekic-Zahirovic; Oliver Sendscheid; Hajer El Oussini; Mélanie Jambeau; Ying Sun; Sina Mersmann; Marina Wagner; Stéphane Dieterlé; Jérome Sinniger; Sylvie Dirrig-Grosch; Kevin Drenner; Marie-Christine Birling; Jinsong Qiu; Yu Zhou; Hairi Li; Xiang-Dong Fu; Caroline Rouaux; Tatyana Shelkovnikova; Anke Witting; Albert C Ludolph; Friedemann Kiefer; Erik Storkebaum; Clotilde Lagier-Tourenne; Luc Dupuis
Journal:  EMBO J       Date:  2016-03-07       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.